Skip to main content
Clinical Trials/NCT01584037
NCT01584037
Withdrawn
Not Applicable

Adenovirus Vaccine Pregnancy Registry

Teva Branded Pharmaceutical Products R&D, Inc.1 site in 1 countryDecember 2011
ConditionsAdenovirus

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Adenovirus
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Locations
1
Primary Endpoint
Adverse Pregnancy Outcome by observation
Status
Withdrawn
Last Updated
12 years ago

Overview

Brief Summary

The primary purpose of the Adenovirus Vaccine Pregnancy Registry is to prospectively collect data concerning:

  1. Pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral,
  2. Potential confounding factors, and
  3. The outcome of these pregnancies.

The secondary purpose of the Adenovirus Vaccine Pregnancy Registry is to evaluate the frequency of birth defects in prospectively enrolled pregnant women. This Registry is also designed to detect any unusual patterns of birth defects.

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
April 2014
Last Updated
12 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • U.S. Military service member, present or former
  • Confirmed exposure to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
  • Received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or has an estimated date of conception (DOC) within 6 weeks after receiving Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
  • Positive β-hCG test or fetal ultrasound,and
  • Verbal and/or written informed consent obtained from the patient.
  • For live born offspring:
  • Infant born to a woman meeting the above inclusion criteria and enrolled in the Registry, followed through one year post delivery, and
  • Verbal and/or written informed consent obtained from the mother of the infant.

Exclusion Criteria

  • Patients who refuse to provide informed consent (verbal or written) to the Institutional Review Board (IRB)-approved informed consent.
  • Females not exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral within the inclusion criteria period.
  • Patients not willing to meet Registry study conditions and requirements.

Outcomes

Primary Outcomes

Adverse Pregnancy Outcome by observation

Time Frame: 12 months

Infants up to 12 months of age

Study Sites (1)

Loading locations...

Similar Trials